Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$36.68 +0.2%	$36.45	$23.42 ▼ $62.58	$2.13B	0.8	1.04 million shs	243,705 shs
BHC Bausch Health Cos	$7.52 +4.8%	$6.30	$4.25 ▼ $9.85	$2.65B	0.41	1.98 million shs	2.76 million shs
OCUL Ocular Therapeutix	$12.65 +1.2%	$10.51	$5.78 ▼ $12.91	$2.17B	1.49	2.12 million shs	1.48 million shs
TERN Terns Pharmaceuticals	$6.77 +4.3%	$4.94	$1.87 ▼ $11.40	$567.95M	-0.05	1.11 million shs	1.21 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+0.19%	-1.03%	-6.40%	+25.70%	-17.91%
BHC Bausch Health Cos	+4.74%	+30.58%	+17.15%	+60.75%	+35.77%
OCUL Ocular Therapeutix	+1.20%	+2.85%	+14.07%	+75.21%	+58.32%
TERN Terns Pharmaceuticals	+4.31%	+20.04%	+34.06%	+135.07%	+4.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3992 of 5 stars	3.4	2.0	4.3	3.3	0.8	1.9
BHC Bausch Health Cos	4.1629 of 5 stars	2.0	4.0	4.0	2.8	3.3	1.3
OCUL Ocular Therapeutix	4.0884 of 5 stars	3.5	3.0	4.1	2.9	1.7	0.0
TERN Terns Pharmaceuticals	4.0271 of 5 stars	3.3	1.0	4.1	3.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$56.33	53.58% Upside
BHC Bausch Health Cos	2.00	Hold	$9.00	19.76% Upside
OCUL Ocular Therapeutix	3.00	Buy	$17.20	35.97% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	130.80% Upside

Current Analyst Ratings Breakdown

Latest TERN, BHC, OCUL, and AGIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	OCUL Ocular Therapeutix	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$22.00 ➝ $20.00
8/5/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $15.00
7/28/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$71.00 ➝ $65.00
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	58.39	N/A	N/A	$23.57 per share	1.56
BHC Bausch Health Cos	$9.63B	0.29	$8.08 per share	0.93	$0.40 per share	18.79
OCUL Ocular Therapeutix	$63.72M	34.54	N/A	N/A	$1.76 per share	7.19
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$3.49 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.00	3.33	N/A	N/A	1,590.42%	-3.49%	-3.23%	10/30/2025 (Estimated)
BHC Bausch Health Cos	-$46M	$0.26	28.90	1.61	N/A	0.99%	-852.36%	5.25%	10/29/2025 (Estimated)
OCUL Ocular Therapeutix	-$193.51M	-$1.28	N/A	N/A	N/A	-382.51%	-71.92%	-49.36%	N/A
TERN Terns Pharmaceuticals	-$88.85M	-$1.04	N/A	N/A	N/A	N/A	-27.35%	-26.18%	N/A

Latest TERN, BHC, OCUL, and AGIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	OCUL Ocular Therapeutix	-$0.35	-$0.39	-$0.04	-$0.39	$13.12 million	$13.46 million
8/5/2025	Q2 2025	TERN Terns Pharmaceuticals	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	-$1.93	-$0.19	-$1.93	$9.46 million	$12.50 million
7/30/2025	Q2 2025	BHC Bausch Health Cos	$0.97	$0.90	-$0.07	$0.40	$2.47 billion	$2.57 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.48	14.04
BHC Bausch Health Cos	141.90	1.31	0.98
OCUL Ocular Therapeutix	0.23	10.10	10.02
TERN Terns Pharmaceuticals	N/A	24.70	24.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
BHC Bausch Health Cos	78.65%
OCUL Ocular Therapeutix	59.21%
TERN Terns Pharmaceuticals	98.26%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
BHC Bausch Health Cos	8.05%
OCUL Ocular Therapeutix	2.30%
TERN Terns Pharmaceuticals	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	58.10 million	55.60 million	Optionable
BHC Bausch Health Cos	20,700	370.13 million	340.33 million	Optionable
OCUL Ocular Therapeutix	230	173.99 million	169.99 million	Optionable
TERN Terns Pharmaceuticals	40	87.51 million	86.20 million	Not Optionable

TERN, BHC, OCUL, and AGIO Headlines

Recent News About These Companies

5 Oral Obesity Drugs Challenging Lilly’s Orforglipron

August 12 at 2:18 AM | biospace.comB

William Blair Has Positive Outlook of TERN FY2025 Earnings

August 9, 2025 | marketbeat.com

Terns Pharmaceuticals (NASDAQ:TERN) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

August 6, 2025 | marketbeat.com

Terns Seeks Partners for Metabolic Assets Amid Oversaturated Obesity Market

August 6, 2025 | biospace.comB

Terns to stop funding metabolic disease trials beyond 2025, seeks partners for assets

August 6, 2025 | fiercebiotech.comF

Terns (TERN) Q2 Net Loss Narrows 16%

August 6, 2025 | fool.com

Brokerages Set Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Target Price at $15.63

August 6, 2025 | americanbankingnews.com

Terns Pharmaceuticals Reports Q2 2025 Financial Results

August 6, 2025 | tipranks.com

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 5, 2025 | globenewswire.com

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

August 4, 2025 | globenewswire.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 3, 2025 | marketbeat.com

Terns Pharmaceuticals (TERN) to Release Quarterly Earnings on Monday

July 28, 2025 | marketbeat.com

Obesity in Focus: ADA Reveals R&D Priorities for Blockbusters-in-Waiting

July 14, 2025 | biospace.comB

Terns Pharmaceuticals CEO & Director Acquires 98% More Stock

July 4, 2025 | finance.yahoo.com

Terns pharmaceuticals CEO Burroughs buys $90k in shares

June 27, 2025 | investing.com

Rivus' weight loss drug scores MASH phase 2 win, showcases muscle-sparing potential

June 26, 2025 | fiercebiotech.comF

Terns Pharmaceuticals Presents Promising Phase 1 Data for TERN-601 at ADA 2025 and Completes Enrollment for Phase 2 FALCON Trial - Nasdaq

June 24, 2025 | nasdaq.com

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American ... - Morningstar

June 24, 2025 | morningstar.comM

Novel GLP-1/GIP Agent Led to Weight Loss With Once-Monthly Dosing

June 23, 2025 | medpagetoday.comM

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

June 23, 2025 | globenewswire.com

Population-Level Weight Loss Seen With Primary Care Protocol

June 21, 2025 | medscape.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TERN, BHC, OCUL, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$36.68 +0.07 (+0.19%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$36.68 0.00 (0.00%)

As of 08/14/2025 05:38 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Bausch Health Cos NYSE:BHC

$7.52 +0.35 (+4.81%)

Closing price 08/14/2025 03:59 PM Eastern

Extended Trading

$7.55 +0.04 (+0.47%)

As of 08/14/2025 07:59 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Ocular Therapeutix NASDAQ:OCUL

$12.65 +0.15 (+1.20%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$12.66 +0.01 (+0.11%)

As of 08/14/2025 07:14 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Terns Pharmaceuticals NASDAQ:TERN

$6.77 +0.28 (+4.31%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$6.76 -0.01 (-0.22%)

As of 08/14/2025 07:46 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time